Ashwinee Kumar Shrestha

Dr. Ashwinee Kumar Shrestha


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2025 in Biochem
Verified
Journal Article
Open access
PDF file
AKAashish Khadka
Aashish Khadka
Bhupendra Raj GIRIBhupendra Raj GIRI
Bhupendra Raj GIRI
RBRishiram Baral
Rishiram Baral
SSShailendra Shakya
Shailendra Shakya
ASAshwinee Kumar Shrestha
Ashwinee Kumar Shrestha
Background/Objectives: Propranolol HCl (PPH), a nonselective beta-adrenergic receptor blocker, is employed as an anti-hypertensive, anti-anginal, anti-arrhythmic, and anti-migraine agent. Given its utility in chronic conditions, developing a sustained-release dosage form becomes imperative to optimize therapeutic outcomes while enhancing patient adherence and minimizing side effects. In this study, we employed a widely adopted matrix-based system to develop PPH sustained-release (PPH-SR) matrix tablets, ensuring the uniform dispersion of the drug within the polymeric matrix to regulate its release rate. Methods: Utilizing cellulose-based polymers, specifically HPMC K100M and ethyl cellulose (EC), as matrix formers, nine different formulations were prepared at varying drug-to-polymer ratios. We employed a wet granulation method, followed by compression of the dried granules, to fabricate round-shaped biconvex PPH-SR tablets. Results: Among these different formulations, formulation 2 (F2), comprising 40 mg PPH and 50 mg HPMC K100M (along with other excipients), showed excellent flowability, as evidenced by Carr’s index and angle of repose values of 12.50 and 28.50, respectively. Additionally, the mechanical properties of F2 tablets showed a hardness of 12.34 ± 0.91 KP, an average weight of 200.45 ± 1.87 mg, with a friability of 0.20%, and a content uniformity of 98.36%. Moreover, in vitro release characteristics of F2 tablets demonstrated a sustained-release behavior, with 94.3 ± 10.2% drug release over 24 h. A comparative analysis with marketed tablets yielded similarity and dissimilarity factors of 64 and 8, respectively. Furthermore, the release profile of F2 exhibited a high degree of linearity with the Korsmeyer–Peppas model (R2 of 0.977), showcasing its reliability and predictability. Conclusions: In essence, this in-house developed PPH sustained-release formulation can improve patient adherence, reduce side effects, and improve therapeutic outcomes. These results align with our objective of enhancing the therapeutic efficacy of PPH and affirm the broader relevance of innovative formulation strategies in addressing the challenges of chronic disease management.

19 September 2025 in The Thai Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
PSPrechha Shrestha
Prechha Shrestha
ASAshwinee Kumar Shrestha
Ashwinee Kumar Shrestha
RSRajan Shrestha
Rajan Shrestha
BTBarsha Thapa
Barsha Thapa
Objectives: The present study utilizes a quality by design approach to develop a simple, robust, and stability-indicating high-performance liquid chromatography method for quantifying dapagliflozin (DAPA) and linagliptin (LINA) in a fixed-dose combination and validate it according to the ICH-Q2 (R1) guidelines. Materials and Methods: The effect of critical method parameters (CMPs), namely percentage of acetonitrile (ACN), pH of the buffer, and flow rate, on critical quality attributes (CQAs) such as retention time, area, tailing factor, and theoretical plates was studied using Box–Behnken design (BBD). Response optimizer was utilized to optimize the experimental conditions. The mobile phase (MP) consisted of ACN and phosphate buffer (0.01 M KH2PO4). The chromatographic separation was performed in C 18 column (250 × 4.6 mm, 5 μm) with ultraviolet (UV) detection set at 225 nm. The method was validated according to the ICH-Q2 (R1) guideline and applied to estimate DAPA and LINA in commercially available fixeddose combination. Results: The study on the effect of the CMPs against the four CQAs using BBD produces second-order polynomial equations. The optimized condition consisted of ACN and phosphate buffer (0.01 M KH2PO4, pH 6.5) in the ratio of 43:57 as a MP maintained at a flow rate of 0.8 mL/min through C 18 column (250 × 4.6 mm, 5 μm) with an oven temperature of 35°C, and UV detection at 225 nm. The method successfully detected the peak of DAPA and LINA at retention times of 4.64 and 7.35 min, respectively, demonstrating good resolution. There was a linear relationship between the concentration of the drugs and their corresponding area, with an R2 value of 0.9975 for DAPA and 0.9996 for LINA over the concentration range of 13.5–24.5 µg/mL and 7.0–13 µg/mL, respectively. The optimized assay conditions were validated according to the ICH-Q2 (R1) guidelines. The method was suitable for the assay of a marketed tablet. The forced degradation study revealed DAPA to be susceptible to alkaline degradation while LINA was prone to acidic, alkaline, oxidative, and photolytic degradation. Conclusion: An analytical method was developed for the quantitative estimation of DAP and LINA using BBD and validated according to the ICH-Q2 (R1) guidelines. The proposed method was utilized for the analysis of drugs in pharmaceutical dosage forms and to assess drug stability under various stress conditions.